Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer

Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.

Oncology Pharmacy Team Jan 22, 2025

Skin Cancer

Promising Combo Therapy Shows High Response Rate in High-Risk Melanoma

New immunotherapy combo shows 55% major pathologic response in high-risk melanoma, activating immune system

Oncology Pharmacy Team Jan 20, 2025

Phase 2 trial combines HDAC inhibitor and PD-1 inhibitor in pancreatic cancer, showing durable responses.

Oncology Pharmacy Team Jan 17, 2025

1 article

Targeted RET inhibitor selpercatinib shows superior efficacy and safety in advanced thyroid cancer trial

Oncology Pharmacy Team Aug 26, 2024